CLINICAL_TRIALS
trial_result
· 2015-10-16
Clinical Trial Update: Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients [Phase 1]
Summary
A Phase 1 trial assessing the bioequivalence of 30 mg and 120 mg nifurtimox tablets in chronic Chagas disease patients; the study has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Chagas Disease | Phase 1 | Status: COMPLETED